ETest in patients with resected pancreatic neuroendocrine tumor
Completed
- Conditions
- pancreatic neuroendocrine tumorpNET1002911210014713
- Registration Number
- NL-OMON44092
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 30
Inclusion Criteria
In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- the patient is 18 years of older
- the patient is primarily treated with a surgical resection for pNET
- the patients is in the follow up program of the Academic Medical Center of Amsterdam (AMC)
- the patients is able to understand the given information
Exclusion Criteria
A potential subject who meets any of the following criteria will be excluded from participation in this study:
- the patient is younger than 18 years
- the patient is not in the follow up program of the AMC
- the patient had metastatic disease at the time of the primary tumor
- the patient is not able to give informed consent
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary outcome is the outcome of the NETest of the patients in the three<br /><br>different groups. A NET score (0-100%) is obtained from algorithmic analyses of<br /><br>PCR data using MATLAB (R2011a, Mathworks, Natick, MA, USA) . A value >= 20% will<br /><br>be considered as a positive test. Scores randing from 0-20% = negative (no<br /><br>evidence of tumor disease activity: NET-negative).<br /><br>Scores ranging from 20-43% are considered *low activity* (NET-positive).<br /><br>Scores ranging from 44-100% are considered *high activity* (NET-positive).</p><br>
- Secondary Outcome Measures
Name Time Method <p>--</p><br>